cleviprex造句

• The maximum infusion rate for Cleviprex is 32 mg / hour.
• Hypotension and reflex tachycardia are potential consequences of rapid upward titration of Cleviprex.
• Cleviprex gives no protection against the effects of abrupt beta-blocker withdrawal.
• Cleviprex contains phospholipids and can support microbial growth.
• Cleviprex is administered intravenously and should be titrated to achieve the desired blood pressure reduction.
• Maintain aseptic technique while handling Cleviprex.
• In clinical studies, no significant changes occurred in serum triglyceride levels in the Cleviprex treated patients.
• In clinical trials, a similar increase in heart rate was observed in both Cleviprex and comparator arms.
• Cleviprex is a single use product that should not be diluted and should not be administered in the same line as other medications.
• Once the stopper is punctured, Cleviprex should be used within 12 hours and any unused portion remaining in the vial should be discarded.
• Because of lipid load restrictions, no more than 1000 mL ( or an average of 21 mg / hour ) of Cleviprex infusion is recommended per 24 hours.
• The incidence of death, stroke, myocardial infarction ( heart attack ), and renal dysfunction at 30 days did not differ significantly between the pooled Cleviprex and comparator treatment arms.
• The ECLIPSE trials consisted of three safety trials in which 1506 patients were randomized to receive Cleviprex, nitroglycerin, sodium nitroprusside, or nicardipine, for the treatment of hypertension associated with cardiac surgery.
• In ESCAPE-2, Cleviprex had a significantly lower rate of treatment failure when compared with placebo ( 8.2 % vs 79.6 % ) and a 91.8 % treatment success rate.
• "' Clevidipine "'( INN, trade name "'Cleviprex "') is a dihydropyridine calcium channel blocker indicated for the reduction of blood pressure when oral therapy is not feasible or not desirable.
• In ESCAPE-1, Cleviprex had a significantly lower rate of treatment failure when compared with placebo ( 7.5 % vs 82.7 % ) and a 92.5 % rate of success in lowering systolic blood pressure ( SBP ) by e " 15 %.
• Cleviprex is contraindicated in patients with allergies to soybeans, soy products, eggs, or egg products; defective lipid metabolism such as pathologic hyperlipemia ( rare genetic disorders characterized by abnormal triglyceride metabolism ), lipoid nephrosis, or acute pancreatitis if it is accompanied by hyperlipidemia; and in patients with severe aortic stenosis.